of value in selecting patients for hormonal treatment, chemotherapy or a combination of both (Salih et al. 1972 , Flax 1973 . New cytotoxic agents are becoming available and their use in combination regimes remains to be explored in conjunction with studies on the timing of administration, cell kinetics, and perhaps the histology and immune status of the tumour.
Quadruple chemotherapy is now established as a significant advance in the treatment of breast cancer, but it is to be hoped that in the next decade all the fragments of research can be combined to provide the solution to this pressing problem.
Dr Evelyn Boesen (Chester Beatty Research Institute): Combinations of cytotoxic drugs are certainly an advance but it will be important to establish standards of measurement of regression of tumours in order to determine the advantage of one regimen over another. Total survival time in regression is more important than the immediate regression rate in breast cancer. It would appear possible at present to select on clinical grounds those tumours unlikely to respond to hormones, and it may be best to use cytotoxic drugs earlier in these cases. Combined treatment with hormones and cytotoxics may have theoretical disadvantages. Hormonal treatment reduces the number of proliferating cells, while antimitotic drugs act mainly on proliferating, cells. Hormonal methods for increasing the rate of cell proliferation have been suggested in order to increase tumour sensitivity to cytotoxics, but this may be dangerous because of the risk of stimulating the formation of cytotoxic-drugresistant lines of cells. There may be advantages in using cytotoxic drugs at an early stage when the mass of tumour cells present is comparatively small. Mr T Hamilton (Edinburgh): 1 have had no response at all to quadruple cytotoxic therapy in patients with advanced disease who have previously been treated by customary hormonal or radiotherapeutic methods. Dr H W C Ward (Birmingham): It has been well established that combination chemotherapy is better than single-agent therapy. The choice of the best combination is difficult, however, because of the number of agents available. Multicentre clinical trials are required to determine the most appropriate combination of drugs. Dr A J Cochran (Glasgow): It should be remembered that cytotoxic chemotherapy is immunosuppressive, and the use of these agents in the treatment of breast cancer may need reappraisal when host defence mechanisms are better understood. Dr K D Bagshawe (London): Many factors are concerned in tumour response. The standard view is that once the bulk of the tumour mass has been sufficiently reduced by the use of chemotherapy, the immune rejection system of the host might be capable of controlling the remainder. However, the problem must be viewed in a broad manner, in that the response to a given tumour represents many factors, additive, synergistic and antagonistic. Cell death may be produced both by chemotherapy and by immune mechanisms. Synchronization of cells for treatment has been widely discussed and, although it is difficult to achieve, progress is being made. It is important to realize that single agents which are effective alone may be ineffective if given in combination. For example, certain antimetabolites appear antagonistic to each other. Mr Ian Burn (Hammersmith Hospital): In the search for effective cytotoxic chemotherapy, emphasis must be given to the search for agents which are cytotoxic to the resting (GO) cells. In the meantime, combination cytotoxic therapy must be investigated in the context of advanced mammary cancer, and especially when there is predictably a low chance of response to major endocrine ablation Mr Michael Baum (The Welsh National School ofMedicine, Cardiff) Immunotherapy in Treatment ofBreast Cancer As our knowledge of the mechanisms of the host response to cancer is incomplete, it is somewhat difficult to discuss the role of immunotherapy in the treatment of breast cancer; my predictions must bejudged against this background ignorance.
At present, it is reasonable to assume that both lymphocytes and macrophages are involved in host response. The thymic-dependent (T) lymphocytes probably play a role in the recognition of tumour cells and the induction of cellular events following this recognition by the release of soluble products known as lymphokines. The lymphocytes in the regional nodes draining breast cancer may have a special role to play in this process as judged by animal experiments (Fisher 1971) .
